The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
33046366
DOI
10.1016/j.urolonc.2020.09.005
PII: S1078-1439(20)30436-1
Knihovny.cz E-zdroje
- Klíčová slova
- Abiraterone, Docetaxel, Enzalutamide, MMP-7, Prostate cancer,
- MeSH
- androsteny terapeutické užití MeSH
- benzamidy terapeutické užití MeSH
- docetaxel terapeutické užití MeSH
- dospělí MeSH
- fenylthiohydantoin terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- matrixová metaloproteinasa 7 krev MeSH
- míra přežití MeSH
- nádory prostaty rezistentní na kastraci krev farmakoterapie mortalita MeSH
- nitrily terapeutické užití MeSH
- prognóza MeSH
- protinádorové látky terapeutické užití MeSH
- retrospektivní studie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- abiraterone MeSH Prohlížeč
- androsteny MeSH
- benzamidy MeSH
- docetaxel MeSH
- enzalutamide MeSH Prohlížeč
- fenylthiohydantoin MeSH
- matrixová metaloproteinasa 7 MeSH
- nitrily MeSH
- protinádorové látky MeSH
OBJECTIVES: The rapidly changing treatment landscape in metastatic castration-resistant prostate cancer (mCRPC) calls for biomarkers to guide treatment decisions. We recently identified MMP-7 as a potential serum marker for the prediction of response and survival in mCRPC patients who received docetaxel (DOC) chemotherapy. Here, we aimed to test this finding in an independent patient cohort and in addition to explore the prognostic potential of serum MMP-7 in abiraterone (ABI) or enzalutamide (ENZA) treated patients. METHODS AND MATERIALS: MMP-7 levels were measured in 836 serum samples from 320 mCRPC patients collected before and during DOC (n = 95), ABI (n = 140), or ENZA (n = 85) treatment by using the ELISA method. Results were correlated with clinical and follow-up data. RESULTS: MMP-7 baseline levels were similar between the 3 treatment groups. In the ABI and ENZA cohorts, baseline MMP-7 levels were lower in patients with prior radical prostatectomy (P = 0.058 and P = 0.041, respectively). Baseline MMP-7 levels above the median were associated with shorter overall survival for the DOC (P = 0.001) and ENZA (P = 0.006) cohorts. Multivariable analyses in the DOC and ENZA cohorts revealed that high pretreatment MMP-7 level is an independent risk factor for patients' survival. In addition, in DOC-treated patients with high baseline MMP-7 level, marker decrease at the third DOC cycle was associated with improved survival. Patients with high baseline MMP-7 levels had better survival when treated with ABI compared to DOC or ENZA. CONCLUSIONS: We confirmed the prognostic value of pretreatment MMP-7 serum level and its changes as independent predictors of survival in DOC-treated mCRPC patients. In addition, high MMP-7 was a negative predictor in ENZA-treated but not in ABI-treated patients. These results warrant further research to confirm the predictive value of serum MMP-7 and to explore the potential mechanistic involvement of MMP-7 in DOC and ENZA resistance of mCRPC patients.
Department of Urology Comprehensive Cancer Centre Medical University of Vienna Vienna Austria
Department of Urology Faculty of Medicine University of Duisburg Essen Essen Germany
Department of Urology Semmelweis University Budapest Hungary
Citace poskytuje Crossref.org
